Levamisole: adjunctive therapy in steroid dependent minimal change nephrotic children

Donia, A. F.; Amer, Galal M.; Ahmed, Hassan A.; Gazareen, Sanaa H.; Moustafa, Fatma E.; Shoeib, Ahmed A.; Ismail, Amani M.; Khamis, Said; Sobh, Mohamed A.
May 2002
Pediatric Nephrology;May2002, Vol. 17 Issue 5, p355
Academic Journal
In children with minimal change nephrotic syndrome (MCNS), the steroid dependent group constitutes an especially difficult case for management. Patients in this group are prone to serious steroid side effects. Additionally, alkylating agents commonly fail to maintain remission and expose patients to more side effects. Therapy with the immunostimulant drug levamisole may therefore be another option in the attempt to maintain remission with minimal side effects. We prospectively treated 20 of our steroid dependent primary MCNS patients with levamisole. All patients were children, with an age range of 3–15 years; 16 were boys and 4 were girls. Remission was firstly induced by steroids, then levamisole was added in a dose of 2.5 mg/kg body weight on alternate days for 6 months. During this period we attempted to withdraw steroids completely and maintain patients on levamisole alone. We followed up our patients for the occurrence of relapse and side effects during this period and for a further 6 months after stopping levamisole. In 11 out of 20 children (55%), we successfully stopped steroids for more than 2 weeks. At the end of the 6-month treatment period (i.e. after 4 months of steroid discontinuation), ten patients (50%) were maintaining remission on levamisole alone. At the end of the 12-month study period (i.e. after 6 months of levamisole discontinuation), five patients (25%) were still in remission without any treatment for the previous 6 months. No significant side effects were reported during levamisole therapy. None of the patients developed neutropenia, but the leukocyte count showed a significant reduction in those who responded to levamisole treatment. We concluded that levamisole therapy for 6 months is a safe and perhaps effective therapy in a subset of children with steroid dependent MCNS to enable an otherwise infeasible withdrawal of steroids. This may be worth a trial before other types of more hazardous adjunctive therapies are considered.


Related Articles

  • Levamisole therapy in corticosteroid-dependent nephrotic syndrome. Bagga, Arvind; Sharma, Amita; Srivastava, R. N. // Pediatric Nephrology;1997, Vol. 11 Issue 4, p415 

    The effect of prolonged treatment with levamisole was examined in 43 patients (30 boys) with steroiddependent nephrotic syndrome (SDNS). The mean age at institution of treatment was 4.0 ± 2.0 years. Fourteen patients had previously received cyclophosphamide with an ensuing remission of 8.5...

  • Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Afzal, Kamran; Bagga, Arvind; Menon, Shina; Hari, Pankaj; Jordan, Stanley C. // Pediatric Nephrology;Dec2007, Vol. 22 Issue 12, p2059 

    The management of patients with steroid-dependent nephrotic syndrome (SDNS) refractory to treatment with long-term steroids, levamisole and cyclophosphamide is difficult. We report our experience on long-term treatment with mycophenolate mofetil (MMF) and alternate-day prednisolone in 42...

  • The use of steroid-sparing agents in steroid-sensitive nephrotic syndrome. Abeyagunawardena, Asiri S.; Dillon, Michael.J.; Rees, Lesley; Hoff, William Vant't; Trompeter, Richard S. // Pediatric Nephrology;Sep2003, Vol. 18 Issue 9, p919 

    Childhood nephrotic syndrome (NS) is frequently characterized by a relapsing course. There is no uniform agreement about the precise stage at which a steroid-sparing agent should be introduced to control the disease. In order to evaluate the treatment strategies and outcome of steroid-sensitive...

  • Levamisole treatment in steroid-sensitive and steroid-resistant nephrotic syndrome. Tenbrock, K.; Müller-Berghaus, J.; Fuchshuber, A.; Michalk, D.; Querfeld, U. // Pediatric Nephrology;1998, Vol. 12 Issue 6, p459 

    Since 1992 we have treated 11 children with frequently relapsing steroid-sensitive (n=6) or steroid-resistant (n=5) nephrotic syndrome with levamisole. All had been non-responsive to other immunosuppressive medication before levamisole treatment. All steroid-sensitive patients had signs of...

  • Efficacy of levamisole in children with frequently relapsing and steroid-dependent nephrotic syndrome. Ekambaram, Sudha; Mahalingam, Vijayakumar; Nageswaran, Prahlad; Udani, Amish; Geminiganesan, Sangeetha; Priyadarshini, Shweta // Indian Pediatrics;May2014, Vol. 51 Issue 5, p371 

    Objectives: To assess the efficacy of levamisole in frequently relapsing nephrotic syndrome and steroid-dependent nephrotic syndrome. Study Design: Retrospective analysis of hospital case records. Setting: Pediatric nephrology department of a tertiary referral pediatric hospital. Participants:...

  • Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise? Davin, J.; Merkus, M. // Pediatric Nephrology;Jan2005, Vol. 20 Issue 1, p10 

    Among the different drugs used for sparing steroids in steroid-sensitive nephrotic syndrome (SSNS) with frequent relapses and steroid dependency, levamisole is the least toxic and the least expensive. However, it is neither approved for this indication nor widely used in Europe. This may be...

  • Effect of Levamisole in Steroid-Dependent Nephrotic Syndrome. Madani, Abbas; Isfahani, Seyed-Taher; Rahimzadeh, Nahid; Fereshtehnejad, Seyed-Mohammad; Hoseini, Rozita; Moghtaderi, Mastaneh; Mohseni, Parvin; Ataiee, Nematollah // Iranian Journal of Kidney Diseases;Oct2010, Vol. 4 Issue 4, p292 

    Introduction. Childhood idiopathic nephrotic syndrome is characterized by frequent relapsing courses or steroid dependency. Levamisole is a popular drug for treatment of these patients. The purpose of this study was to evaluate levamisole in children with steroid-dependent nephrotic syndrome....

  • Bone disease in nephrotic syndrome-prevention is better than cure. Gulati, Sanjeev; Gulati, Kiran // Pediatric Nephrology;Jan2005, Vol. 20 Issue 1, p111 

    Among the different drugs used for sparing steroids in steroid-sensitive nephrotic syndrome (SSNS) with frequent relapses and steroid dependency, levamisole is the least toxic and the least expensive. However, it is neither approved for this indication nor widely used in Europe. This may be...

  • Disseminated autoimmune disease during levamisole treatment of nephrotic syndrome. Barbano, G.; Ginevri, Fabrizio; Ghiggeri, Gian M.; Gusmano, Rosanna // Pediatric Nephrology;1999, Vol. 13 Issue 7, p602 

    Side effects such as cutaneous vasculitis, which occur during prolonged levamisole treatment, may discourage the utilization of the drug in relapsing nephrotic syndrome. We describe a child who developed disseminated vasculitis during prolonged treatment with levamisole. The acute phase was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics